# Indo Us Biotech (NSE: INDOUS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/INDOUS · Pivot · prices to 22 Oct 2026

Indo Us Biotech (NSE: INDOUS) closed at ₹67.96 on 22 Oct 2026, down 0.06% on the day. With a market capitalisation of ₹136 Cr, it ranks 2481st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Cement & Materials sector; its industry is Agricultural Inputs.

At its last close the stock traded at 10.4× trailing earnings, against a return on equity of 13.1% in FY22. Over the past year the share price has fallen 47.3%. Its 52-week range is ₹65.00 (21 Oct 2026) to ₹159.00 (27 Nov 2025); the last close is 57.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹26 Cr (−22.0% year on year) and net profit ₹2 Cr (−46.5%), on a standalone basis. Promoters held 68.29% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹67.96 |
| Market cap | ₹136 Cr |
| P/E (trailing) | 10.4 |
| ROE | 13.1% (FY22) |
| ROCE | 15.0% (FY22) |
| Debt to equity | 0.33 |
| 52-week high | ₹159.00 (27 Nov 2025) |
| 52-week low | ₹65.00 (21 Oct 2026) |
| 1-year return | −47.3% |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹26 Cr | −22.0% | ₹2 Cr | −46.5% | ₹0.98 |
| Q3 FY26 | ₹23 Cr | −3.2% | ₹3 Cr | −40.6% | ₹1.49 |
| Q2 FY26 | ₹31 Cr | +39.2% | ₹3 Cr | −20.9% | ₹1.72 |
| Q1 FY26 | ₹31 Cr | +24.5% | ₹5 Cr | +48.3% | ₹2.35 |
| Q4 FY25 | ₹33 Cr | +111.7% | ₹4 Cr | +607.7% | ₹1.86 |
| Q3 FY25 | ₹24 Cr | +6.6% | ₹5 Cr | +37.2% | ₹2.52 |
| Q2 FY25 | ₹22 Cr | +40.2% | ₹4 Cr | +161.1% | ₹2.16 |
| Q1 FY25 | ₹25 Cr | +29.2% | ₹3 Cr | +33.8% | ₹1.58 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY22 | ₹50 Cr | ₹5 Cr |
| FY21 | ₹40 Cr | ₹5 Cr |
| FY20 | ₹40 Cr | ₹3 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 68.29%
- Foreign institutions: 0.01%
- Non-institutions: 31.70%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Kaira Can](https://app.pivotnow.in/stock/KAIRA) | — | ₹143 Cr | — | — |
| [Prima Plastics](https://app.pivotnow.in/stock/PRIMAPLA) | — | ₹143 Cr | — | — |
| [Duroply Industr](https://app.pivotnow.in/stock/DUROPLY) | — | ₹140 Cr | — | — |
| [Texmo Pipes and Products](https://app.pivotnow.in/stock/TEXMOPIPES) | ₹46.70 | ₹136 Cr | 9.8 | — |
| [The Western India Plywoods](https://app.pivotnow.in/stock/WIPL) | ₹160.00 | ₹136 Cr | 186 | — |
| [Hindprakash Industries](https://app.pivotnow.in/stock/HPIL) | ₹116.20 | ₹133 Cr | 48.4 | — |

## Questions and answers

### What is the share price of Indo Us Biotech today?

Indo Us Biotech (NSE: INDOUS) last closed at ₹67.96 on 22 Oct 2026. Its 52-week high is ₹159.00 and its 52-week low is ₹65.00.

### What is the market cap of Indo Us Biotech?

Indo Us Biotech's market capitalisation is ₹136 Cr (₹136 Cr) at the 22 Oct 2026 close, ranking 2481st among the NSE companies Pivot tracks.

### What is the P/E ratio of Indo Us Biotech?

Indo Us Biotech trades at a trailing P/E of 10.4. The median P/E of the 3 closest Cement & Materials peers by market cap is 48.4.

### What is the ROE and ROCE of Indo Us Biotech?

Return on equity was 13.1% in FY22 and return on capital employed was 15.0% in FY22 (consolidated figures).

### Is Indo Us Biotech a debt-free company?

No. Indo Us Biotech's debt-to-equity ratio was 0.33 in FY22, with total debt of ₹4 Cr.

### What were Indo Us Biotech's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Indo Us Biotech reported revenue of ₹26 Cr, −22.0% year on year, and net profit of ₹2 Cr, −46.5% year on year.

### How has Indo Us Biotech stock performed over the last year?

Indo Us Biotech's share price has fallen 47.3% over the past year, −21.5% over three months and −13.4% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Indo Us Biotech?

As of 30 Jun 2026: promoters 68.29%, foreign institutions 0.01%, non-institutions 31.70%.

### Who are Indo Us Biotech's competitors?

The listed Cement & Materials companies closest to Indo Us Biotech by market cap are Kaira Can, Prima Plastics, Duroply Industr, Texmo Pipes and Products, The Western India Plywoods and Hindprakash Industries.

### Is Indo Us Biotech a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Indo Us Biotech's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on INDOUS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.